Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 3
2019 2
2020 5
2021 9
2022 9
2023 6
2024 55
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference.
Kloske CM, Belloy ME, Blue EE, Bowman GR, Carrillo MC, Chen X, Chiba-Falek O, Davis AA, Paolo GD, Garretti F, Gate D, Golden LR, Heinecke JW, Herz J, Huang Y, Iadecola C, Johnson LA, Kanekiyo T, Karch CM, Khvorova A, Koppes-den Hertog SJ, Lamb BT, Lawler PE, Guen YL, Litvinchuk A, Liu CC, Mahinrad S, Marcora E, Marino C, Michaelson DM, Miller JJ, Morganti JM, Narayan PS, Naslavsky MS, Oosthoek M, Ramachandran KV, Ramakrishnan A, Raulin AC, Robert A, Saleh RNM, Sexton C, Shah N, Shue F, Sible IJ, Soranno A, Strickland MR, Tcw J, Thierry M, Tsai LH, Tuckey RA, Ulrich JD, van der Kant R, Wang N, Wellington CL, Weninger SC, Yassine HN, Zhao N, Bu G, Goate AM, Holtzman DM. Kloske CM, et al. Alzheimers Dement. 2024 Sep;20(9):6590-6605. doi: 10.1002/alz.13877. Epub 2024 Jul 19. Alzheimers Dement. 2024. PMID: 39031528 Free PMC article. Review.
INTRODUCTION: The apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid-beta and tau pathologies but also lipid and …
INTRODUCTION: The apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease …
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.
Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, Triana-Baltzer G, Du-Cuny L, Li Y, Coomaraswamy J, Baratta M, Mordashova Y, Saad ZS, Raunig DL, Ashton NJ, Meyers EA, Rubel CE, Rosenbaugh EG, Bannon AW, Potter WZ; Alzheimer's Disease Neuroimaging Initiative (ADNI) Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team. Schindler SE, et al. Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12. Alzheimers Dement. 2024. PMID: 39394841 Free PMC article.
INTRODUCTION: Blood tests have the potential to improve the accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access to AD-specific treatments. This study compared leading commercial blood tests for amyloid pathology and other …
INTRODUCTION: Blood tests have the potential to improve the accuracy of Alzheimer's disease (AD) clinical diagnosis, wh …
The informatics of ADNI.
Toga AW, Neu S, Sheehan ST, Crawford K; Alzheimer's Disease Neuroimaging Initiative. Toga AW, et al. Alzheimers Dement. 2024 Oct;20(10):7320-7330. doi: 10.1002/alz.14099. Epub 2024 Aug 14. Alzheimers Dement. 2024. PMID: 39140398 Free PMC article. Review.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has revolutionized the landscape of Alzheimer's research through its Informatics Core, which has facilitated unprecedented data standardization and sharing. ...HIGHLIGHTS: Accelerating bioma …
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has revolutionized the landscape of Alzheimer's re …
The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact.
Kalaria R, Maestre G, Mahinrad S, Acosta DM, Akinyemi RO, Alladi S, Allegri RF, Arshad F, Babalola DO, Baiyewu O, Bak TH, Bellaj T, Brodie-Mends DK, Carrillo MC, Celestin KK, Damasceno A, de Silva RK, de Silva R, Djibuti M, Dreyer AJ, Ellajosyula R, Farombi TH, Friedland RP, Garza N, Gbessemehlan A, Georgiou EE, Govia I, Grinberg LT, Guerchet M, Gugssa SA, Gumikiriza-Onoria JL, Hogervorst E, Hornberger M, Ibanez A, Ihara M, Issac TG, Jönsson L, Karanja WM, Lee JH, Leroi I, Livingston G, Manes FF, Mbakile-Mahlanza L, Miller BL, Musyimi CW, Mutiso VN, Nakasujja N, Ndetei DM, Nightingale S, Novotni G, Nyamayaro P, Nyame S, Ogeng'o JA, Ogunniyi A, de Oliveira MO, Okubadejo NU, Orrell M, Paddick SM, Pericak-Vance MA, Pirtosek Z, Potocnik FCV, Raman R, Rizig M, Rosselli M, Salokhiddinov M, Satizabal CL, Sepulveda-Falla D, Seshadri S, Sexton CE, Skoog I, George-Hyslop PHS, Suemoto CK, Thapa P, Udeh-Momoh CT, Valcour V, Vance JM, Varghese M, Vera JH, Walker RW, Zetterberg H, Zewde YZ, Ismail O. Kalaria R, et al. Alzheimers Dement. 2024 Jun;20(6):4290-4314. doi: 10.1002/alz.13836. Epub 2024 May 2. Alzheimers Dement. 2024. PMID: 38696263 Free PMC article. Review.
Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo.
Pichet Binette A, Mammana A, Wisse L, Rossi M, Strandberg O, Smith R, Mattsson-Carlgren N, Janelidze S, Palmqvist S; ADNI; Ticca A, Stomrud E, Parchi P, Hansson O. Pichet Binette A, et al. Alzheimers Dement. 2024 Nov;20(11):7624-7634. doi: 10.1002/alz.14225. Epub 2024 Sep 11. Alzheimers Dement. 2024. PMID: 39258841 Free PMC article.
INTRODUCTION: We examined the relations of misfolded alpha synuclein (alpha-synuclein) with Alzheimer's disease (AD) biomarkers in two large independent cohorts. METHODS: We included Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Tw …
INTRODUCTION: We examined the relations of misfolded alpha synuclein (alpha-synuclein) with Alzheimer's disease (AD) bi …
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C, Bateman RJ, Holtzman DM, Irizarry M, Verbel D, Sachdev P, Ito S, Contois J, Yarasheski KE, Braunstein JB, Verghese PB, West T. Meyer MR, et al. Alzheimers Dement. 2024 May;20(5):3179-3192. doi: 10.1002/alz.13764. Epub 2024 Mar 16. Alzheimers Dement. 2024. PMID: 38491912 Free PMC article.
BACKGROUND: With the availability of disease-modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment …
BACKGROUND: With the availability of disease-modifying therapies for Alzheimer's disease (AD), it is important f …
No association between markers of systemic inflammation and endothelial dysfunction with Alzheimer's disease progression: a longitudinal study.
van Setten A, Uleman JF, Melis RJF, Lawlor B, Riksen NP, Claassen JAHR, de Heus RAA; NILVAD Study Group. van Setten A, et al. Geroscience. 2024 Jul 31. doi: 10.1007/s11357-024-01294-x. Online ahead of print. Geroscience. 2024. PMID: 39085534
INTRODUCTION: Systemic inflammation and endothelial dysfunction are potentially modifiable factors implicated in Alzheimer's disease (AD), which offer potential therapeutic targets to slow disease progression. ...We employed individual growth models to …
INTRODUCTION: Systemic inflammation and endothelial dysfunction are potentially modifiable factors implicated in Alzheimer's …
Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring.
Petersen ME, Flores-Aguilar L, Head E, Montoliu-Gaya L, Strydom A, Pape SE, Fortea J, Ashton NJ, Udeh-Momoh C, O'Bryant SE, German D, Despa F, Mapstone M, Zetterberg H. Petersen ME, et al. Alzheimers Dement. 2024 Nov 13. doi: 10.1002/alz.14364. Online ahead of print. Alzheimers Dement. 2024. PMID: 39535517
Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diagnostic determination of Alzheimer's Disease in Down Syndrome (DS-AD) remains challenging in clinical settings. ...HIGHL …
Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diag …
Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a non-demented Alzheimer's risk-enhanced sample.
Du L, Langhough RE, Wilson RE, Reyes RER, Hermann BP, Jonaitis EM, Betthauser TJ, Chin NA, Christian B, Chaby L, Jeromin A, Molfetta GD, Brum WS, Arslan B, Ashton N, Blennow K, Zetterberg H, Johnson SC. Du L, et al. Alzheimers Dement. 2024 Sep;20(9):6183-6204. doi: 10.1002/alz.14100. Epub 2024 Jul 5. Alzheimers Dement. 2024. PMID: 38970274 Free PMC article.
INTRODUCTION: Understanding longitudinal change in key plasma biomarkers will aid in detecting presymptomatic Alzheimer's disease (AD). METHODS: Serial plasma samples from 424 Wisconsin Registry for Alzheimer's Prevention participants were analy …
INTRODUCTION: Understanding longitudinal change in key plasma biomarkers will aid in detecting presymptomatic Alzheimer's d …
Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers.
Liu S, Park T, Krüger DM, Pena-Centeno T, Burkhardt S, Schutz AL, Huang YN, Rosewood T, Chaudhuri S, Cho M, Risacher SL, Wan Y, Shaw LM, Sananbenesi F, Brodsky AS, Lin H, Krunic A, Blusztajn JK, Saykin AJ, Delalle I, Fischer A, Nho K; Alzheimer's Disease Neuroimaging Initiative. Liu S, et al. Alzheimers Dement. 2024 Nov;20(11):7698-7714. doi: 10.1002/alz.14230. Epub 2024 Sep 18. Alzheimers Dement. 2024. PMID: 39291737 Free PMC article.
INTRODUCTION: MicroRNAs (miRNAs) play important roles in gene expression regulation and Alzheimer's disease (AD) pathogenesis. METHODS: We investigated the association between baseline plasma miRNAs and central AD biomarkers from the Alzheimer' …
INTRODUCTION: MicroRNAs (miRNAs) play important roles in gene expression regulation and Alzheimer's disease (AD) pathog …
86 results